Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula (1):



wherein:

Cy is a group of Formula (2):



an optionally substituted heterocyclic ring, C_{3-7}cycloalkyl or phenyl;

R_1, R_2, R_3, R_4 and R_5 are hydrogen, halogen, hydroxy, amino, trifluoromethyl or nitrile and at least one of R_1, R_2, R_3, R_4 and R_5 is halogen, trifluoromethyl or nitrile;

R_6 is hydrogen, optionally substituted straight-chained or branched C_{1-3}alkyl, amino or hydroxy;

R_7 is hydrogen, optionally substituted straight-chained or branched C_{1-3}alkyl, optionally substituted amino or hydroxy;

R_8 is hydrogen, methyl or ethyl;

R_9 is optionally substituted straight-chained or branched C_{1-6}alkyl, optionally substituted straight-chained or branched C_{2-6}alkenyl, optionally substituted straight-chained or branched C_{2-6}alkynyl, C_{3-7}cycloalkyl or optionally substituted phenyl;

R_{20} is hydrogen or straight-chained or branched C_{1-3}alkyl or R_9 and R_{20} may together form C_{3-7}cycloalkyl;

R_{10} is hydrogen or straight-chained or branched C_{1-3}alkyl;

R_{11} is hydrogen, optionally substituted straight-chained or branched C_{1-3}alkyl, $-CO-N(R_{14})R_{15}$, carboxyl ~~or an optionally substituted heterocyclic ring~~;

R_{12} is hydroxy or $-OR_{16}$;

R_{13} is hydrogen, straight-chained or branched C_{1-6}alkyl, straight-chained or branched C_{2-6}alkenyl, straight-chained or branched C_{2-6}alkynyl or a group of Formula (3):



R_{14} and R_{15}, which may be the same or different, are hydrogen, optionally substituted straight-chained or branched C_{1-4}alkyl, C_{3-7}cycloalkyl, straight-chained or branched C_{1-4}alkyloxy, straight-chained or branched C_{1-4}alkylsulfonyl or a heterocyclic ring, or R_{14} and R_{15}, as $-N(R_{14})R_{15}$, form optionally substituted 3- to 7-membered cyclic amine;

R_{16} is straight-chained C_{1-4}alkyl;

R_{17} is hydrogen or methyl;

R_{18} and R_{19} together form cycloalkyl or C_{3-7}cycloalkenyl;

X is carbonyl or methylene;

Y is carbonyl or methylene;

provided that

when Cy is 3-indolyl,

~~(i) R_{11} is an optionally substituted heterocyclic ring; or~~

~~(ii)~~ R_6 is hydrogen, R_7 is amino, R_8 is methyl, R_9 is isopropyl, R_{20} is hydrogen, R_{10} is methyl, R_{11} is carbamoyl, R_{12}

is hydroxy, R_{13} is tert-butyl, X is carbonyl and Y is carbonyl, ~~and~~

~~when Cy is cyclohexyl or phenyl, R_{11} is an optionally substituted heterocyclic ring;~~

or a hydrate or pharmaceutically acceptable salt thereof.

2. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2);
or a hydrate or pharmaceutically acceptable salt thereof.

3. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R_1, R_2, R_3, R_4 and R_5 is halogen and the others are hydrogen or hydroxy;
or a hydrate or pharmaceutically acceptable salt thereof.

4. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is halogen or R_2 and R_3 are the same kind of halogen;
or a hydrate or pharmaceutically acceptable salt thereof.

5. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is halogen and R_1, R_2, R_4 and R_5 are hydrogen, or R_2 and R_3 are the same kind of halogen and R_1, R_4 and R_5 are hydrogen;
or a hydrate or pharmaceutically acceptable salt thereof.

6. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R_1, R_2, R_3, R_4 and R_5 is trifluoromethyl and the others are hydrogen, halogen or hydroxy;
or a hydrate or pharmaceutically acceptable salt thereof.

7. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R_1, R_2, R_3, R_4 and R_5 is nitrile and the others are hydrogen, halogen or hydroxy;
or a hydrate or pharmaceutically acceptable salt thereof.

8. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is trifluoromethyl;
or a hydrate or pharmaceutically acceptable salt thereof.

9. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is nitrile;
or a hydrate or pharmaceutically acceptable salt thereof.

10. (Currently Amended) The compound according to claim 1,
wherein Cy in Formula (1) is an optionally substituted heterocyclic ring provided that when Cy is 3-indolyl,
(i) ~~R_{11} is an optionally substituted heterocyclic ring; or~~
~~(ii)~~ R_6 is hydrogen, R_7 is amino, R_8 is methyl, R_9 is isopropyl, R_{20} is hydrogen, R_{10} is methyl, R_{11} is carbamoyl, R_{12} is hydroxy, R_{13} is tert-butyl, X is carbonyl and Y is carbonyl;
or a hydrate or pharmaceutically acceptable salt thereof.

Claims 11-12. (Canceled)

13. (Previously Presented) The compound according to claim 1, wherein R_6 in Formula (1) is hydrogen or methyl;
or a hydrate or pharmaceutically acceptable salt thereof.

14. (Previously Presented) The compound according to claim 1, wherein R_7 in Formula (1) is hydrogen or optionally substituted amino; or a hydrate or pharmaceutically acceptable salt thereof.

15. (Previously Presented) The compound according to claim 1, wherein R_8 in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

16. (Previously Presented) The compound according to claim 1, wherein R_9 in Formula (1) is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, cyclohexylmethyl or para-fluorobenzyl;
or a hydrate or pharmaceutically acceptable salt thereof.

17. (Previously Presented) The compound according to claim 1, wherein R_{20} in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

18. (Previously Presented) The compound according to claim 1, wherein R_{10} in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

19. (Currently Amended) The compound according to claim 1, wherein R_{11} in Formula (1) is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, tertbutylcarbamoyl, ~~2-pyridylcarbamoyl,~~ methoxycarbamoyl, ~~2-thiazolyl, 1,3,4-oxadiazol-2-yl, 1,2,4-~~

~~oxadiazol-5-yl, 1,3,4-triazol-2-yl, 6-methyl-4-pyrimidinon-2-yl,~~ methylcarbamoyl, methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl, ~~1-morpholinylcarbonyl, 4-carboxymethyl-1-piperazinecarbonyl, 4-ethoxycarbonylmethyl-1-piperazinecarbonyl or 4-methylsulfonyl-1-piperazinecarbonyl~~; or a hydrate or pharmaceutically acceptable salt thereof.

20. (Previously Presented) The compound according to claim 1, wherein R_{12} in Formula (1) is hydroxy; or a hydrate or pharmaceutically acceptable salt thereof.

21. (Previously Presented) The compound according to claim 1, wherein R_{13} in Formula (1) is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl; or a hydrate or pharmaceutically acceptable salt thereof.

22. (Currently Amended) The compound according to claim 1, wherein in Formula (1) Cy is a group of Formula (2) in which at least one of R_1, R_2, R_3, R_4 and R_5 is halogen and the others are hydrogen or hydroxy;
R_6 is hydrogen or methyl;
R_7 is hydrogen or optionally substituted amino;
R_8 is hydrogen or methyl;
R_9 is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, para-fluorobenzyl or cyclohexylmethyl;
R_{20} is hydrogen;
R_{10} is hydrogen or methyl;
R_{11} is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl,

cyclopropylcarbamoyl, tert-butylcarbamoyl, ~~2-pyridylcarbamoyl~~, methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl, or methoxycarbamoyl, ~~1-morpholinylcarbonyl, 4-carboxymethyl-1-piperazinecarbonyl, 4-ethoxycarbonylmethyl-1-piperazinecarbonyl, 4-methylsulfonyl-1-piperazinecarbonyl, 2-thiazolyl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-triazol-2-yl or 6-methyl-4-pyrimidinon-2-yl~~;

R_{12} is hydroxy;

R_{13} is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl;

or a hydrate or pharmaceutically acceptable salt thereof.

23. (Original) The compound according to claim 1 which is selected from the group of compounds consisting of Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-Cl)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(3,4-F_2)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHOMe, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(2-pyridylcarbamoyl)ethylamide, N-(2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-3-(3-tBu-4-hydroxyphenyl)propyl)urea, N-(2-(2-(2-amino-3-(4-fluorophenylpropanoyl-N-methylamino)-3-methyl)butyrylamino)-3-(3-tertbutyl-4-hydroxyphenyl)propyl)sulfamide, N-[2-(3-tertbutyl-4-hydroxyphenyl)-1-(methanesulfonylaminomethyl)ethyl]-2-[N-(4-fluorophenylalanyloyl)methylamino]-3-methylbutanamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-carbamidemethylethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-methanesulfonylmethylethylamide,

2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-3-(3-tBu-4-hydroxyphenyl)propanol, 2-(1-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-2-(3-tertbutyl-4-hydroxyphenyl)ethyl)-6-methyl-4-pyrimidinone, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-oxadiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,2,4-oxadiazol-5-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(thiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-triazol-2-yl)ethylamide, Tyr(2-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Tyr(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH_2, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH_2, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH_2, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH_2, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val- N-Et-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHtBu, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2SO_2CH_3$, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-

Val-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)- NHEt, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHcPr, and Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHnPr Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHiPr;
or a hydrate or pharmaceutically acceptable salt thereof.

24. (Previously Presented) A pharmaceutical composition containing an effective amount of the compound according to claim 1 as an active ingredient and an inert pharmaceutically acceptable carrier.

25. (Previously Presented) A motilin receptor antagonist composition containing an effective amount of the compound according to claim 1 and an inert pharmaceutically acceptable carrier.

Claims 26-27. (Cancelled)

28. (Currently Amended) A compound of Formula (4):



wherein

Cy, R_6, R_8, R_9, R_{20}, R_{10}, R_{12}, R_{13}, X and Y are as defined in claim 1;

R_7' is hydrogen, straight-chained or branched C_{1-3}alkyl optionally having at least one protected substituent, amino optionally having at least one protected substituent or protected hydroxy; and

R_{11}" is hydrogen, optionally substituted straight-chained or branched C_{1-3}alkyl, -CO-N(R_{14})R_{15}, wherein R_{14} and R_{15} are as defined in claim 1, carboxyl, straight-chained or branched C_{1-3}alkyl having a protected amino ~~or an optionally substituted heterocyclic ring~~;

or a hydrate or pharmaceutically acceptable salt thereof.

29. (Currently Amended) A compound of Formula (5):



wherein:

Cy, R_6, R_8, R_9, R_{20}, R_{10}, R_{12}, R_{13}, X and Y are as defined in claim 1;

R_7" is hydrogen, straight-chained or branched C_{1-3}alkyl optionally having at least one optionally protected substituent, amino optionally having at least one optionally protected substituent or optionally protected hydroxy; and

R_{11}' is hydrogen, straight-chained or branched C_{1-3}alkyl optionally having at least one protected substituent, -CO-N(R_{14})R_{15} wherein R_{14} and R_{15} are as defined in claim 1, carboxyl ~~or an optionally substituted heterocyclic ring;~~

or a hydrate or pharmaceutically acceptable salt thereof.

30. (Previously Presented) A compound of Formula (6):



wherein:

R_8 is hydrogen, optionally-substituted straight-chained or branched C_{1-3} alkyl, optionally substituted amino, or hydroxy;

R_9, is optionally-substituted straight-chained or branched C_{1-6} alkyl, optionally substituted straight-chained or branched C_{2-6} alkenyl, optionally substituted straight-chained or branched C_{2-6} alkynyl, C_{3-7} cycloalkyl or optionally substituted phenyl;

R_{20} is hydrogen or straight-chained or branched C_{1-3} alkyl;

R_{10} is hydrogen or straight-chain or branched C_{1-3} alkyl;

R_{12} is hydroxy or ORO_{16};

R_{13} is hydrogen, straight-chained or branched C_{2-6} alkenyl, straight-chained or branched C_{2-6} alkynyl or a group of Formula (3)



Wherein R_{17} is hydrogen or methyl;

R_{18} and R_{19} together form cycloalkenyl or C_{3-7} cycloalkenyl; and

Y is carbonyl or methylene;

P_1 is hydrogen or a protecting group of amine; and

R_{11}''' is hydrogen, optionally substituted straight-chained or branched C_{1-3}alkyl, $-CO-N(R_{14})R_{15}$ wherein R_{14} and R_{15}, which may be the same or different, are hydrogen, optionally substituted straight-chained or branched C_{1-4} alkyl, C_{3-7} cycloalkyl, straight-chained or branched C_{1-4} alkoxy, straight-chained or branched C1-alkylsulfonyl or a heterocyclic ring, or R_{14} and R_{15}, as $-N(R_{14})R_{15}$, form optionally substituted 3-7 cyclic amine, carboxyl, straight-chained or branched C_{1-3}alkyl having protected amino or an optionally substituted heterocyclic ring;
or a hydrate or pharmaceutically acceptable salt thereof.

Claims 31-34. (Canceled)